Company / R&D Expense
BioMarin Pharmaceutical R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$921.9M
FY2025
5-year range
$628.8M / $921.9M
FY2021-FY2025
Trend
+23.4%
vs FY2024
Sector context
#20 of 210
Health Care
What the data says
Among 210 Health Care companies, BioMarin Pharmaceutical is in the top 10% for r&d expense. R&D Expense has increased for 5 consecutive years, from $628M in FY2020 to $922M in FY2025.
Based on SEC 10-K filings.
$922M in FY2025 with a 5-year CAGR of +8.0%. Top quartile in the Health Care sector.
Improved from $747M to $922M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +12.4%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 210This company $921.9M Sector average $644.1M
▼
+43.1% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, r&d expense increased 23.4% year-over-year.
- Ranks #20 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $921.9M | +23.4% |
| FY2024 | $747.2M | +0.1% |
| FY2023 | $746.8M | +15.0% |
| FY2022 | $649.6M | +3.3% |
| FY2021 | $628.8M | +0.1% |
| FY2020 | $628.1M | -12.2% |
| FY2019 | $715.0M | +2.7% |
| FY2018 | $696.3M | +14.0% |
| FY2017 | $610.8M | -7.7% |
| FY2016 | $661.9M | +4.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026